Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Zenz

Blood

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Blood|March 2, 2013
Exhausting T cells in CLLThorsten Zenz
Blood|October 31, 2015
Mutational landscape and complexity in CLLThorsten Zenz, Wolfgang Huber
Blood|August 14, 2010
CLL 17p deletion: more than 'miR'ly p53?Thorsten Zenz, Stephan Stilgenbauer
Blood|March 8, 2012
Risk categories and refractory CLL in the era of chemoimmunotherapyThorsten Zenz, John G Gribben, Michael Hallek, et al.
Blood|January 26, 2013
Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironmentAngela Schulz, Claudia Dürr, Thorsten Zenz, et al.
Blood|March 18, 2015
Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signalingRegina Jitschin, Martina Braun, Mirjeta Qorraj, et al.
Blood|March 26, 2010
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemiaMaike Buchner, Constance Baer, Gabriele Prinz, et al.
Blood|August 12, 2008
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-upThorsten Zenz, Alexander Kröber, Katrin Scherer, et al.
Blood|October 19, 2018
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cellsEleni Kabrani, Van Trung Chu, Evangelia Tasouri, et al.
Blood|May 27, 2006
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemiaThorsten Zenz, Matthias Ritgen, Peter Dreger, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Blood|March 2, 2013
Exhausting T cells in CLLThorsten Zenz
Blood|October 31, 2015
Mutational landscape and complexity in CLLThorsten Zenz, Wolfgang Huber
Blood|August 14, 2010
CLL 17p deletion: more than 'miR'ly p53?Thorsten Zenz, Stephan Stilgenbauer
Blood|March 8, 2012
Risk categories and refractory CLL in the era of chemoimmunotherapyThorsten Zenz, John G Gribben, Michael Hallek, et al.
Blood|January 26, 2013
Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironmentAngela Schulz, Claudia Dürr, Thorsten Zenz, et al.
Blood|March 18, 2015
Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signalingRegina Jitschin, Martina Braun, Mirjeta Qorraj, et al.
Blood|March 26, 2010
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemiaMaike Buchner, Constance Baer, Gabriele Prinz, et al.
Blood|August 12, 2008
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-upThorsten Zenz, Alexander Kröber, Katrin Scherer, et al.
Blood|October 19, 2018
Nuclear FOXO1 promotes lymphomagenesis in germinal center B cellsEleni Kabrani, Van Trung Chu, Evangelia Tasouri, et al.
Blood|May 27, 2006
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemiaThorsten Zenz, Matthias Ritgen, Peter Dreger, et al.
Pageof 4